| 1,207 | 16 | 3 |
| 下载次数 | 被引频次 | 阅读次数 |
肝损伤已经成为严重损害人类健康的疾病之一，药物使用不当、饮酒过量、环境污染等因素均会对肝细胞产生损害，其持续发展会导致肝纤维化、肝硬化、肝癌等严重不良后果。黄芪-丹参药对中含有黄芪总皂苷、黄芪总多糖、丹参总酚酸、丹参总多糖、丹参酮等多种化学成分，两种药单独应用或者联合应用可治疗化学性肝损伤、免疫性肝损伤、急性肝损伤及其并发症等多种疾病。该文通过查阅国内外有关黄芪-丹参药对在改善肝损伤方面发挥作用的化学成分和具体机制相关文献，梳理了黄芪-丹参多种化学成分通过多靶点、多指标发挥改善肝损伤作用，阐述其治疗肝损伤的作用机制，发现中药在调理人体健康、治疗慢性疾病的独特优势，以期为黄芪-丹参药对的开发研究提供参考。
Abstract：Liver injury has become one of the diseases that seriously damage human health. Improper use of drugs,excessive drinking,environmental pollution and other factors will cause damage to liver cells,and its continued development will lead to serious consequences such as liver fibrosis,cirrhosis and liver cancer. Huangqi(Astragali Radix)-Danshen(Salviae Miltiorrhizae)drug pair contains many chemical components,such as Astragalus membranaceus total saponins,Astragalus membranaceus total polysaccharides,Salvia miltiorrhiza total phenolic acids,Salvia miltiorrhiza total polysaccharides,tanshinone,etc. The two drugs can be used alone or in combination to treat various diseases such as chemical liver injury,immune liver injury,acute liver injury and its complications. In this paper,the chemical constituents and mechanism of Huangqi(Astragali Radix)-Danshen(Salviae Miltiorrhizae)drug pair in improving liver injury were reviewed,and various chemical constituents of Huangqi(Astragali Radix)-Danshen(Salviae Miltiorrhizae)improved liver injury through multi-target and multi-index effects.The mechanism of treating liver injury was expounded,and the unique advantages of traditional Chinese medicine in regulating human health and treating chronic diseases were found,so as to provide reference for the development and research of Huangqi(Astragali Radix)-Danshen(Salviae Miltiorrhizae)drug pair.
[1]黄鹏，邱华，李家焕.中医药治疗自身免疫性肝病研究进展[J].河南中医，2020,40(1):134-139.
[2]王南丁，王文杰，王新冰，等.芪丹通脉片对Apo E（-/-）小鼠动脉粥样硬化易损斑块TLR4/NF-κB信号转导通路的影响[J].中国中西医结合杂志，2019,39(8):971-977.
[3]LEE JS,CHO JH,LEE DS,et al.Genotoxicity evaluation of an ethanol extract mixture of Astragali Radix and Salviae miltiorrhizae Radix[J].Evid Based Complement Alternat Med,2018,2018:1-6.
[4]WU C,KAN H,HU M,et al.Compound Astragalus and Salvia miltiorrhiza extract inhibits hepatocarcinogenesisvia modulating TGF-β/TβR and Imp7/8[J].Exp Ther Med,2018,16(2):1052-1060.
[5]何国鑫，邓青芳，陈华国，等.杠板归乙醇提取物对化学性肝损伤小鼠的保护作用[J].中成药，2019,41(6):1253-1257.
[6]ABIRAMI A,NAGARANI G,SIDDHURAJU P.Hepatoprotective effect of leaf extracts from Citrus hystrix and C.maxima against paracetamol induced liver injury in rats[J].Food Science and Human Wellness,2015,4(1):35-41.
[7]陈雪龙，齐艳萍.四氯化碳急性肝损伤小鼠血清及肝脏组织学变化[J].中国兽医杂志，2011,47(1):39-40,98.
[8]胡妮娜，张晓娟.黄芪的化学成分及药理作用研究进展[J].中医药信息，2021,38(1):76-82.
[9]李颖，赵增成，林树乾，等.丹参主要化学成分及提取分离方法研究进展[J].中医药学报，2021,49(1):106-111.
[10]GUI S Y,WEI W,WANG H,et al.Effects and mechanisms of crude astraga-losides fraction on liver fibrosis in rats[J].Ethnopharmacol,2006,103(2):154-159.
[11]叶枝红，谢海纳，钱知知，等.黄芪甲苷对“铁超载”所致小鼠肝损伤的保护作用[J].中国实验方剂学杂志，2018,24(8):116-121.
[12]郑小蓉.黄芪多糖对镉染毒大鼠肝脏损伤的保护作用[J].工业卫生与职业病，2018,44(6):418-420,426.
[13]李伟霞，刘现磊，唐进法，等.黄芪-丹参药对活性成分网络药理学研究[J].中医学报，2017,32(11):2171-2175,2180.
[14]陈燕芬，王磊，陈丽娟，等.不同产地丹参及丹参配伍黄芪前后有效成分含量测定[J].中国药房，2012,23(3):237-239.
[15]祁晓霞，董宇，单晨啸，等.基于UFLC-Q-TOF/MS分析黄芪-丹参药对化学成分研究[J].南京中医药大学学报，2017,33(1):93-96.
[16]阎小女，王金茹，韩子岩.丹参与黄芪配伍干预四氯化碳诱导大鼠肝损害的实验研究[J].山西医科大学学报，2014,45(6):450-452,545.
[17]朱黎霞，张英丰.不同配比黄芪丹参对气虚血瘀证模型大鼠血液流变学及TXB2、6-keto-PGFα影响的研究[J].中国医药导报，2014,11(22):13-15,19.
[18]李均，王冬，曹轶璇，等.黄芪丹参有效组分不同比例配伍对肾纤维化模型大鼠肾小管上皮细胞转分化的影响[J].上海中医药大学学报，2012,26(1):68-72.
[19]LIU X,CHEN J,LIU X,et al.Jian-Pi-Yi-Shen Formula ameliorates chronic kidney disease:involvement of mitochondrial quality control network[J].BMC Complement Altern Med,2018,18(1):340.
[20]刘晓颖，冀爱英.以黄芪针丹参针为主治疗老年肝硬化56例[J].中西医结合肝病杂志，1996,6(3):38.
[21]易善华，李永福.黄芪注射液与丹参注射液合用治疗慢性肝炎肝硬化43例[J].中国药业，2010,19(12):77.
[22]王文斌，张健.黄芪与丹参合用治疗慢性活动性肝炎的疗效分析[J].齐齐哈尔医学院学报，2000,21(2):172.
[23]黄建生.复方丹参滴丸加黄芪对乙肝肝硬化肝纤维化指标的影响[J].湖南中医杂志，2006,22(3):17-18.
[24]王兴，吴长健，王晏.黄芪合丹参注射液治疗慢性乙型肝炎疗效观察[J].现代中西医结合杂志，2000,9(21):2087-2089.
[25]朱孝武，阮怀定.黄芪并丹参注射液治疗慢性乙型肝炎疗效观察[J].皖南医学院学报，2000,19(3):222.
[26]陈丰，陈绍红，柳海艳，等.辅助性保护化学性肝损伤保健食品配方的特点分析[J].中草药，2018,49(7):1703-1709.
[27]孙克诚，何亚兰，张乐，等.黄芪甲苷对扑热息痛诱导肝损伤小鼠炎症因子表达的影响[J].安徽科技学院学报，2019,33(6):33-37
[28]王珏，李琴，李颖.黄芪总皂苷对CCl4诱导急性肝损伤小鼠保护作用及机制初探[J].中药药理与临床，2018,34(6):70-73.
[29]姜雪梅，王晶，朱英伟，等.丹参酮IIA协同振动运动改善糖尿病大鼠肝损伤状态[J].中药药理与临床，2016,32(6):75-78.
[30]陈兰羽，孙婷婷，朱丹，等.黄芪甲苷联合丹参酚酸B对肝细胞过氧化损伤的保护作用及其机制研究[J].辽宁中医杂志，2019,46(7):1488-1490,1569.
[31]肖日传，罗光明，张风波，等.栀子根醇提物对CCl4致小鼠急性肝损伤的保护作用[J].中药药理与临床，2017,33(3):114-117.
[32]徐飞，李伟荣.黄芪甲苷对CCL4所致肝损伤大鼠的保护作用[J].实用肝脏病杂志，2019,22(6):808-811.
[33]舒慧，魏蕾.黄芪预防小鼠急性酒精性肝损伤的作用机制研究[J].湖北科技学院学报（医学版），2012,26(6):470-472.
[34]姚莹华，刘强，陈育尧，等.丹参多糖对小鼠急性肝损伤的保护作用[J].中国实验方剂学杂志，2010,16(6):227-230.
[35]刘文艺，吴鸿.黄芪丹参合剂对小鼠CCl4急性肝损伤保护作用的实验研究[J].中国实验诊断学，2011,15(8):1293-1295.
[36]KIM J W,LEE Y S,SEOL D J,et al.Anti-obesity and fatty liver-preventing activities of Lonicera caerulea in high-fat dietfed mice[J].Int J Mol Med,2018,42(6):3047-3064.
[37]严文瑞，王玲芝，候玲玲，等.复方黄芪益气口服液对AFB1所致大鼠急性肝损伤的保护作用[J].山西医科大学学报，2019,50(10):1435-1439.
[38]徐源，黄存东，李竹青，等.黄芪甲苷对糖尿病大鼠肝损伤保护作用及其机制研究[J].安徽医科大学学报，2017,52(12):1823-1829.
[39]陈智阳，黄江山，徐燕军，等.丹参酮ⅡA减轻脓毒症大鼠急性肝肾损伤[J].中国免疫学杂志，2020,36(13):1578-1582.
[40]黄晓菡.丹芪活肝胶囊对急性肝损伤保护作用的实验研究[D].广州：广州医学院，2009.
[41]钱倩宇，应娜，杨贞，等.丹参酮ⅡA通过激活PPARα减轻4-HNE诱导的肝细胞损伤的机制研究[J].中国中药杂志，2019,44(9):1862-1868.
[42]关翠雯，金晶，李佳，等.丹参酮ⅡA激活Nrf2/ARE通路保护雷公藤甲素所致急性肝损伤[J].药学学报，2013,48(9):1397-1402.
[43]韩超，王霄，杨金凯，等.丹参多糖缓解免疫性肝损伤的机制[J].中国兽医学报，2018,38(9):1761-1765.
[44]李胜男，王蓉，吴斌，等.注射用丹参多酚酸盐通过调节NF-κB/IκB和p38 MAPK信号通路防治胆汁淤积性肝损伤[J].中南药学，2019,17(3):332-337.
[45]WU C T,DENG J S,HUANG W C,et al.Salvianolic acid Cagainst acetaminophen-induced acute liver injury by attenuating inflammation,oxidative stress,and apoptosis through inhibition of the Keap1/Nrf2/HO-1 signaling[J].Oxid Med Cell Longev,2019,2019:1-13.
[46]ZENG W,SHAN W,GAO L,et al.Inhibition of HMGB1 release via salvianolic acid B-mediated SIRT1 up-regulation protects rats against non-alcoholic fatty liver disease[J].Sci Rep,2015,5:16013.
[47]WU C,CHEN W,FANG M,et al.Compound Astragalus and Salvia miltiorrhiza extract inhibits hepatocellular carcinoma progression via mi R-145/mi R-21 mediated Smad3phosphorylation[J].J Ethnopharmacol,2019,231:98-112.
[48]HU X,RUI W,WU C,et al.Compound Astragalus and Salvia miltiorrhiza extracts suppress hepatocarcinogenesis by modulating transforming growth factor-β/Smad signaling[J].JGastroenterol Hepatol,2014,29(6):1284-1291.
[49]RUI W,XIE L,LIU X,et al.Compound Astragalus and Salvia miltiorrhiza extract suppresses hepatocellular carcinoma progression by inhibiting fibrosis and PAI-1 m RNAtranscription[J].J Ethnopharmacol,2014,151(1):198-209.
[50]罗千古，周玖瑶，李毓祺，等.黄芪丹参提取液对小鼠免疫系统的影响[J].中国医药导报，2011,8(2):23-24.
[51]王霄，秦姣姣，魏媛媛，等.丹参多糖对免疫性肝损伤小鼠肝脏凋亡因子的影响[J].中国兽医学报，2019,39(10):2047-2054.
[52]YAN X,JIANG Z,BI L,et al.Salvianolic acid A attenuates TNF-α-and D-Gal N-induced ER stress-mediated and mitochondrial-dependent apoptosis by modulating Bax/Bcl-2ratio and calcium release in hepatocyte LO2 cells[J].Naunyn Schmiedebergs Arch Pharmacol,2015,388(8):817-830.
[53]来季华.丹参合并黄芪对慢性肝炎、肝硬化抗纤维化治疗疗效及预后分析[J].中成药，2003,25(8):88-90.
[54]谭友文，殷玉梅，於学军，等.丹参、黄芪对肝硬化门静脉高压患者血流动力学及肝纤维化指标的影响[J].中国中西医结合杂志，2001,21(5):351-353.
[55]YALCIN A,YUMRUTAS O,KULOGLU T,et al.Hepatoprotective properties for Salvia cryptantha extract on carbon tetrachloride-induced liver injury[J].Cell Mol Biol,2017,63(12):56-62.
[56]王晓慧，杨波，周忠光，等.药食两用中药及活性成分抗肝损伤研究进展[J].辽宁中医药大学学报，2021,23(5):138-141.
[57]王荣荣，吕佳霖，贺明帅，等.苍耳子致小鼠肝损伤1H-NMR代谢组学分析[J].辽宁中医药大学学报，2021,23(10):34-39.
基本信息:
DOI：10.13194/j.issn.1673-842x.2022.05.002
中图分类号:R285
引用信息:
[1]王艳宏,杨雪,栾宁等.黄芪-丹参药对改善肝损伤化学成分及作用机制研究进展[J].辽宁中医药大学学报,2022,24(05):5-9.DOI:10.13194/j.issn.1673-842x.2022.05.002.
基金信息:
黑龙江中医药大学科研基金（2018jkcy03）